Type IV Collagen Induces Matrix Metalloproteinase 2 Activation in HT1080 Fibrosarcoma Cells
Overview
Authors
Affiliations
Matrix metalloproteinase 2 (MMP-2) activation has been described as a "master switch" which triggers tumor spread and metastatic progression. We show here that type IV collagen, a major component of basement membranes, promotes MMP-2 activation by HT1080 cells. When plated on plastic, HT1080 cells constitutively processed the 66-kDa pro-MMP-2 into a 62-kDa intermediate activated form, most probably through a membrane type (MT) 1 MMP-dependent mechanism. In the presence of type IV collagen, part of this intermediate form was further processed to fully activated 59-kDa MMP-2. This activation was prevented by tissue inhibitor of MMP (TIMP)-2 and a broad-spectrum hydroxamic acid-based synthetic MMP inhibitor (GI129471). Type IV collagen-mediated pro-MMP-2 activation did not involve either a transcriptional modulation of MMP-2, MT1-MMP, or TIMP-2 expression nor any alteration of MT1-MMP protein synthesis or processing. An inverse relationship between MMP-2 activation and the concentration of secreted TIMP-2 was observed. This is consistent with our previous report that TIMP-2 degradation is probably linked to the MT1-MMP-dependent MMP-2 activation mechanism. Because invasive tumor cells must breach basement membranes at different steps of the metastatic dissemination, the ability of HT1080 cells to activate pro-MMP-2 in the presence of type IV collagen might represent a key regulatory mechanism for the acquisition of an invasive potential.
Peeney D, Liu Y, Lazaroff C, Gurung S, Stetler-Stevenson W Carcinogenesis. 2022; 43(5):405-418.
PMID: 35436325 PMC: 9167030. DOI: 10.1093/carcin/bgac037.
Can VEGFC Form Turing Patterns in the Zebrafish Embryo?.
Wertheim K, Roose T Bull Math Biol. 2019; 81(4):1201-1237.
PMID: 30607882 PMC: 6397306. DOI: 10.1007/s11538-018-00560-2.
Lambert E, Fuselier E, Ramont L, Brassart B, Dukic S, Oudart J Sci Rep. 2018; 8(1):9837.
PMID: 29959360 PMC: 6026150. DOI: 10.1038/s41598-018-28003-x.
Cepeda M, Pelling J, Evered C, Williams K, Freedman Z, Stan I Mol Cancer. 2016; 15(1):65.
PMID: 27756325 PMC: 5070195. DOI: 10.1186/s12943-016-0547-x.
Hammer A, Diakonova M Adv Exp Med Biol. 2014; 846:97-137.
PMID: 25472536 PMC: 4576997. DOI: 10.1007/978-3-319-12114-7_5.